W. Zoli et al., ESTABLISHMENT AND CHARACTERIZATION OF 2 NEW CELL-LINES DERIVED FROM HUMAN METASTATIC BREAST CARCINOMAS, Breast cancer research and treatment, 43(2), 1997, pp. 141-151
Two human cancer cell lines (MA 2 and MA 3) were established from pleu
ral effusions of infiltrating ductal carcinomas of the breast. The lin
es were maintained in continuous monolayer culture with doubling times
of 70 (MA 2) and 78 (MA 3) hr for more than two years and possessed e
xtensively rearranged abnormal karyotypes with modal chromosome number
of 83 (MA 2) and 81 (MA 3) and DNA index values of 1.65 and 1.77, res
pectively. No amplifications or rearrangements were evident in the c-m
yc, int-2, c-erb B2, c-Ha-ras, or hst 1 genes in MA 2 and MA 3 cell li
nes. The clinical histories of the patients from whom the cell lines w
ere derived are reported and compared with the results observed in the
cell lines in vitro. The presence of CEA, CA 15-3, and MCA tumor mark
ers observed in the primary tumor tissues was retained by the establis
hed cell lines. While the primary tumor tissues were ER+/PgR borderlin
e + (MA 2) and ER-/PgR+ (MA 3), the MA 2 line was ER+/PgR- and the MA
3 line remained ER-/PgR+. The MDR P-glycoprotein was not expressed eit
her in primary tumor tissues or in the respective cell lines. High exp
ression of cytokeratins 7, 18, and 19 was evident by immunohistochemic
al analysis in each cell line, whereas cytokeratins 8 and 17 were poor
ly or not at all expressed. The treatment history of the patients from
whom the cell lines were derived involved CMF followed six months lat
er by novantrone and cisplatin plus VP 16 (MA 2) and FEC followed four
years later by CMF (MA 3). The chemosensitivity pattern assay of the
cell lines indicated that the MA 2 line was sensitive to doxorubicin,
cisplatin, and vinblastine, whereas the MA 3 line was sensitive to dox
orubicin and cisplatin. The characteristics of these cell lines indica
te them to be a good experimental model to investigate breast cancer b
iology and anticancer drug response.